Treximet Early Intervention Adolescent Migraine

Adolescent Migraine Clinical Trial

— TEAM  

Official title:

Early Intervention, Randomized, Mulitcenter, Placebo-Controlled, 4-Period Crossover, Multi-Attack Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01016678
• Other study ID #: TEAM2009
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: November 18, 2009
• Last updated: October 27, 2014
• Start date: March 2010
• Est. completion date: July 2014

Study information

• Verified date: October 2014
• Source: Premiere Research Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study involves approximately 105 adolescent (ages 12-17) subjects to be screened at 4 sites across the US. All subjects enrolled will treat up to 4 MILD migraines over a 6 month period. They will be required to have three office visits during the six months. All subjects will be randomized to either Treximet (85mg Imitrex/500mg Naproxen Sodium) or Placebo (sugar-pill) in four of the five treatment arms with a 3 to 1 ratio. A fifth treatment arm will treat all 4 migraines with active drug, Treximet. The hypothesis is that Treximet will prove to be a safe and effective treatment for this population, that has so few treatment for migraine. And Treximet will be superior over placebo for pain free endpoints at 2 and 24 hours.

Description:

There are two primary treatment comparisons for this study: 1) the percentage of subjects' pain free at 2 hours after treatment with TREXIMET versus placebo across attacks, and 2) the percentage of subjects who are sustained pain free at 24 hours after treatment with TREXIMET versus placebo across attacks.

The following alternative hypothesis will be tested to see if there is a difference in the proportion of subjects who are pain free at 2 hours with TREXIMET versus placebo at all attacks, OR there is a difference in the proportion of subjects who are sustained pain free at 24 hours with TREXIMET versus placebo at all attacks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 104
• Est. completion date: July 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects between the ages of 12-17.

2. Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least 1 but no more than 8 attacks per month on average over the past 6 months prior to screening visit. Attacks should be moderate to severe and last for at least 3 hours.

3. Subject is able to distinguish migraine from other headaches and can determine when a mild headache will become a moderate/severe migraine.

4. Female subjects are eligible for participation provided they are of non-child bearing potential or if started menses; they are on a stable regimen of approved contraception.

5. Subject and subject's parent or legal guardian are able to read and write English.

6. Subject is able to read, comprehend, and complete subject diaries.

7. Subjects' parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.

8. Subject is willing and able to provide Informed Assent prior to entry into the study.

Exclusion Criteria

Subjects meeting any of the following criteria must not be enrolled in the study:

1. Subject is < 74 pounds (33.3kg) and no greater than 260lbs (117.9kg)

2. Subject has greater than or equal to 15 headache days per month in total.

3. Subject has secondary headaches i.e. complex migraine, hemiplegic, or basilar.

4. Subject, in investigators opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.

5. Subject has uncontrolled hypertension at screening or is taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.

6. Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in the study.

7. Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with the above.

8. Subject has a evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an anti-epileptic drug for seizure control within 5 years prior to screening.

9. Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.

10. Subject has a hypersensitivity, allergy, intolerance, or contraindication to the use any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps or asthma.

11. Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized for at least two months for either chronic or intermittent migraine prophylaxis or other co-morbid condition.

12. Subject has taken or plans to take a monoamine oxidase inhibitor (MAOI) including herbal preparations containing St. Johns Wort (Hypericum perforatum), anytime within the two weeks prior to screening and two weeks past exit of study.

13. Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.

14. Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.

15. Subject is pregnant, actively trying to become pregnant, or breast feeding or Subject is not willing to have pregnancy test(s).

16. Subject has evidence of illicit drug or alcohol abuse within the last year or any concurrent psychiatric condition which, in the investigator's opinion, will likely interfere with study conduct and participation in the trial.

17. Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adolescent Migraine
• Migraine Disorders

Intervention

Drug:
• Treximet
85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.

Locations

Country	Name	City	State
United States	Andrew Hershey	Cincinnati	Ohio
United States	Steve L. Linder	Dallas	Texas
United States	Don W. Lewis	Norfolk	Virginia
United States	Premiere Research Institute	West Palm Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Premiere Research Institute	GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment comparisons between TREXIMET and placebo will be used to support the conclusions of consistency of response to TREXIMET across attacks. The primary parameters of interest are the 2-hour pain free and 24 hour sustained pain free.		2 years	No
Secondary	All related symptoms and use of rescue medications will be analyzed for secondary outcome measures. Patient safety will be analyzed as well.		2 years	Yes